Newron Pharmaceuticals said last week that it has appointed Stefan Weber as chief financial officer, and Ravi Anand as chief medical officer.
Weber joins Newron from drug discovery and development firm Biofrontera, where he served as CFO. Prior to this, he was CFO at Girindus. He began his career with the Lohmann Group, a worldwide producer of pharmaceutical, medical, technical, and consumer products, Newron said.
Anand most recently served as an independent consultant to the global pharmaceutical industry, Newron said. He has held senior research positions at Hoffman La Roche, Sandoz/Novartis, and Organon.
Newron, based in Milan, Italy, is leading an Ion Channel Screening Project under the auspices of the European Comission's Sixth Framework Program for Research and Development (see CBA News, 12/7/2004).
Fisher Scientific has named Matthew Friel as senior vice president of corporate development.
According to the company, Friel was most recently with GenTek, where he served as executive vice president of finance and business development, as well as vice president and CFO. Before this, he was a managing director at Latona Associates, a merchant banking firm acting as both a principal and an advisor in mergers, acquisitions, divestitures, and project-financing transactions. Friel has also served as an assistant director in the mergers and acquisitions group of Barclays de Zoete Wedd, the investment banking arm of Barclays Bank, Fisher said. He has a BS in business administration from Georgetown University, and an MBA from Harvard Business School.
Invitrogen said last week that it has named Mark Gardner as its chief marketing officer.
Gardner has been with Invitrogen since 2003, serving in such roles as vice president of process development and vice president of commercial marketing. He previously worked for General Electric Medical Systems in its information technologies division.